Abstract:BACKGROUND: Lung squamous cell carcinoma (LUSC) is characterized by frequent mutations of tumor protein p53 (TP53) and cyclin dependent kinase inhibitor 2A (CDKN2A). However, to date, the impact of TP53/CDKN2A status on the clinical outcome of patients with early-stage LUSC is unclear.METHODS: Tissue samples from 16 early-stage, surgically resected LUSCs were analyzed by next-generation sequencing (NGS). Information regarding TP53 and CDKN2A alterations and patient survival time was downloaded from The Cancer Genome Atlas (TCGA) database. The associations between TP53 and CDKN2A status and tumor characteristics, outcomes including overall survival (OS) and disease-free survival (DFS), and mutation counts were investigated.RESULTS: TP53 and CDKN2A exhibited a high frequency of somatic mutations in early-stage LUSC in our center. Data for 1,176 samples were collected from TCGA. CDKN2A mutation status was associated with TP53 mutation status (P=0.040). TP53 mutation was a favorable prognostic factor for early-stage LUSC. The OS times of patients with wild-type and mutated TP53 were 28.94 and 60.48 months, respectively (P=0.002). In contrast, CDKN2A mutations were significantly associated with a shorter survival time in early-stage LUSC. The OS times for wild-type and mutated CDKN2A patients were 62.81 and 37.55 months, respectively (P=0.026). Patients with TP53 mutations had higher total mutation counts compared to patients with wild-type TP53. Furthermore, OS was significantly shorter in patients with a low mutation count compared to patients with a median or high mutation count.CONCLUSIONS: Early-stage LUSC patients with TP53 mutations had a longer OS, while those with CDKN2A mutations had a shorter OS. Furthermore, patients with TP53 mutation/CDKN2A wild-type status had a longer OS. CDKN2A mutation is a vital indicator for prognostic assessment according to TP53 status. The prolonged survival of patients with TP53 mutations may be due to their high mutation counts. Larger datasets are required to validate these observations.

Figure S1 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Figure S1 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S3 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S2 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S1 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

CD45+CD326+ Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Supplementary Figure 1 from Detection and Dynamic Changes of <i>egfr</i> Mutations from Circulating Tumor DNA As a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

Prognostic Roles Of Ctla-4 And Pdcd1 Gene Expression In Non-Small Cell Lung Cancer

Figure S6 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer

TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes

Supplementary Figure S1 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

P1.02-049 Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients

TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC

Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Table S2 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Impact Of Genetic Alterations On Outcomes Of Patients With Stage I Nonsmall Cell Lung Cancer: An Analysis Of The Cancer Genome Atlas Data

P2.01-45 Clinico-Molecular Characteristics and Prognostic Outcomes of TP53 Mutated Patients with Advanced Non-Small Cell Lung Cancer

Figure S1 from CD45&lt;sup&gt;+&lt;/sup&gt;CD326&lt;sup&gt;+&lt;/sup&gt; Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Figure S1 from CD45&lt;sup&gt;+&lt;/sup&gt;CD326&lt;sup&gt;+&lt;/sup&gt; Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S3 from CD45&lt;sup&gt;+&lt;/sup&gt;CD326&lt;sup&gt;+&lt;/sup&gt; Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S2 from CD45&lt;sup&gt;+&lt;/sup&gt;CD326&lt;sup&gt;+&lt;/sup&gt; Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S1 from CD45&lt;sup&gt;+&lt;/sup&gt;CD326&lt;sup&gt;+&lt;/sup&gt; Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

CD45+CD326+ Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Supplementary Figure 1 from Detection and Dynamic Changes of &lt;i&gt;egfr&lt;/i&gt; Mutations from Circulating Tumor DNA As a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

Prognostic Roles Of Ctla-4 And Pdcd1 Gene Expression In Non-Small Cell Lung Cancer

Figure S6 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer

TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes

Supplementary Figure S1 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

P1.02-049 Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients

TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC

Supplementary Figure S6 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

Supplementary Table S2 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Impact Of Genetic Alterations On Outcomes Of Patients With Stage I Nonsmall Cell Lung Cancer: An Analysis Of The Cancer Genome Atlas Data

P2.01-45 Clinico-Molecular Characteristics and Prognostic Outcomes of TP53 Mutated Patients with Advanced Non-Small Cell Lung Cancer

Figure S1 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Figure S1 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S3 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S2 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Table S1 from CD45<sup>+</sup>CD326<sup>+</sup> Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Supplementary Figure 1 from Detection and Dynamic Changes of <i>egfr</i> Mutations from Circulating Tumor DNA As a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC